CIK 0001664710 · Non-accelerated filer<br>Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 811173868
- Phone
- 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $10,270
- in 1 filing
- Open-market sales, last 90 days
- $101,136
- in 4 filings, $6K under 10b5-1 plans
Net −$90,866. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 78 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-30 | Kariv Tomer Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2024-05-30 | Nussbaum Ran Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2024-05-30 | Knowles Julius Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2024-05-30 | GRAY MARY ANN Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2024-05-30 | GORDON CARL L Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2024-05-30 | Farzan Nima Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2024-02-23 | Seehra Jasbir CHIEF EXECUTIVE OFFICER | Grant or award · Employee Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2024-02-13 | Seehra Jasbir CHIEF EXECUTIVE OFFICER | Grant or award · Employee Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2024-02-13 | Regnante Keith CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-02-13 | Rovaldi Christopher CHIEF OPERATING OFFICER | Grant or award · Employee Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2024-02-13 | Cooper Simon Peter CHIEF MEDICAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-01-04 | Regnante Keith CHIEF FINANCIAL OFFICER | Option exercise | +40,000 | $16.00 | $640K | 40,000 |
| 2024-01-04 | Regnante Keith CHIEF FINANCIAL OFFICER | Sale | −40,000 | $45.29 | $1.8M | 0 |
| 2024-01-04 | Regnante Keith Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) | −40,000 | 53,622 | ||
| 2023-11-04 | Regnante Keith Chief Financial Officer | Option exercise | +40,000 | $16.00 | $640K | 40,000 |
| 2023-11-04 | Regnante Keith Chief Financial Officer | Sale | −40,000 | $45.29 | $1.8M | 0 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Option exercise 10b5-1 | +20,000 | $16.00 | $320K | 20,000 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Sale 10b5-1 | −15,993 | $45.03 | $720K | 4,007 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Sale 10b5-1 | −1,428 | $46.46 | $66K | 2,579 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Sale 10b5-1 | −2,579 | $47.25 | $122K | 0 |
Page 6 of 9 · 173 trades